WO1992000983A1 - Composition non corrosive et procedes utiles dans l'extraction d'acides nucleiques - Google Patents
Composition non corrosive et procedes utiles dans l'extraction d'acides nucleiques Download PDFInfo
- Publication number
- WO1992000983A1 WO1992000983A1 PCT/US1991/004932 US9104932W WO9200983A1 WO 1992000983 A1 WO1992000983 A1 WO 1992000983A1 US 9104932 W US9104932 W US 9104932W WO 9200983 A1 WO9200983 A1 WO 9200983A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extraction
- benzyl alcohol
- group
- nucleic acid
- sample
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 116
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 114
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 114
- 238000000605 extraction Methods 0.000 title claims abstract description 106
- 238000000034 method Methods 0.000 title claims abstract description 66
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 230000009972 noncorrosive effect Effects 0.000 title description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims abstract description 72
- 239000008346 aqueous phase Substances 0.000 claims abstract description 39
- 150000002894 organic compounds Chemical group 0.000 claims abstract description 24
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000000440 bentonite Substances 0.000 claims abstract description 22
- 229910000278 bentonite Inorganic materials 0.000 claims abstract description 22
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 22
- 230000002934 lysing effect Effects 0.000 claims abstract description 17
- 230000003196 chaotropic effect Effects 0.000 claims abstract description 14
- 150000001875 compounds Chemical class 0.000 claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 10
- MSHFRERJPWKJFX-UHFFFAOYSA-N 4-Methoxybenzyl alcohol Chemical compound COC1=CC=C(CO)C=C1 MSHFRERJPWKJFX-UHFFFAOYSA-N 0.000 claims description 8
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims description 8
- 238000002955 isolation Methods 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- XPNGNIFUDRPBFJ-UHFFFAOYSA-N (2-methylphenyl)methanol Chemical compound CC1=CC=CC=C1CO XPNGNIFUDRPBFJ-UHFFFAOYSA-N 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- -1 -OH Chemical group 0.000 claims description 5
- 238000005192 partition Methods 0.000 claims description 5
- PDYCXUZHSKLETQ-UHFFFAOYSA-N (3-ethoxyphenyl)methanol Chemical compound CCOC1=CC=CC(CO)=C1 PDYCXUZHSKLETQ-UHFFFAOYSA-N 0.000 claims description 4
- FEOMFFKZOZMBKD-UHFFFAOYSA-N (4-phenoxyphenyl)methanol Chemical compound C1=CC(CO)=CC=C1OC1=CC=CC=C1 FEOMFFKZOZMBKD-UHFFFAOYSA-N 0.000 claims description 4
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 4
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 claims description 4
- 239000004101 4-Hexylresorcinol Substances 0.000 claims description 2
- WFJIVOKAWHGMBH-UHFFFAOYSA-N 4-hexylbenzene-1,3-diol Chemical compound CCCCCCC1=CC=C(O)C=C1O WFJIVOKAWHGMBH-UHFFFAOYSA-N 0.000 claims description 2
- 235000019360 4-hexylresorcinol Nutrition 0.000 claims description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004202 carbamide Substances 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 229960003258 hexylresorcinol Drugs 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 235000019445 benzyl alcohol Nutrition 0.000 abstract description 22
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 abstract description 16
- 150000003839 salts Chemical class 0.000 abstract description 7
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 62
- 239000000523 sample Substances 0.000 description 44
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 28
- 238000009396 hybridization Methods 0.000 description 28
- 229960004217 benzyl alcohol Drugs 0.000 description 22
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 20
- 108020004414 DNA Proteins 0.000 description 18
- 102000053602 DNA Human genes 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 17
- 238000003556 assay Methods 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 239000012074 organic phase Substances 0.000 description 15
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 14
- 239000012472 biological sample Substances 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 238000005119 centrifugation Methods 0.000 description 11
- 229920002477 rna polymer Polymers 0.000 description 11
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 10
- 230000003321 amplification Effects 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 238000003199 nucleic acid amplification method Methods 0.000 description 10
- 239000008188 pellet Substances 0.000 description 10
- 239000006166 lysate Substances 0.000 description 9
- 238000003752 polymerase chain reaction Methods 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 101710163270 Nuclease Proteins 0.000 description 8
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 8
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000007983 Tris buffer Substances 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 239000000975 dye Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- 239000003599 detergent Substances 0.000 description 6
- 230000002550 fecal effect Effects 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 108010067770 Endopeptidase K Proteins 0.000 description 5
- 229940016590 sarkosyl Drugs 0.000 description 5
- 108700004121 sarkosyl Proteins 0.000 description 5
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 102000006382 Ribonucleases Human genes 0.000 description 4
- 108010083644 Ribonucleases Proteins 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 150000003951 lactams Chemical class 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000004677 Nylon Substances 0.000 description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 238000005191 phase separation Methods 0.000 description 3
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 3
- 231100000167 toxic agent Toxicity 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 2
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 229940122426 Nuclease inhibitor Drugs 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 241000605862 Porphyromonas gingivalis Species 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 238000002820 assay format Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000002051 biphasic effect Effects 0.000 description 2
- 239000004927 clay Substances 0.000 description 2
- ZXJXZNDDNMQXFV-UHFFFAOYSA-M crystal violet Chemical group [Cl-].C1=CC(N(C)C)=CC=C1[C+](C=1C=CC(=CC=1)N(C)C)C1=CC=C(N(C)C)C=C1 ZXJXZNDDNMQXFV-UHFFFAOYSA-M 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000011536 extraction buffer Substances 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- PZYDAVFRVJXFHS-UHFFFAOYSA-N n-cyclohexyl-2-pyrrolidone Chemical compound O=C1CCCN1C1CCCCC1 PZYDAVFRVJXFHS-UHFFFAOYSA-N 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 108020004418 ribosomal RNA Proteins 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 238000012421 spiking Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000006163 transport media Substances 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- BCHIXGBGRHLSBE-UHFFFAOYSA-N (4-methyl-2-oxochromen-7-yl) dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C=CC2=C1OC(=O)C=C2C BCHIXGBGRHLSBE-UHFFFAOYSA-N 0.000 description 1
- WDQFELCEOPFLCZ-UHFFFAOYSA-N 1-(2-hydroxyethyl)pyrrolidin-2-one Chemical compound OCCN1CCCC1=O WDQFELCEOPFLCZ-UHFFFAOYSA-N 0.000 description 1
- NJPQAIBZIHNJDO-UHFFFAOYSA-N 1-dodecylpyrrolidin-2-one Chemical compound CCCCCCCCCCCCN1CCCC1=O NJPQAIBZIHNJDO-UHFFFAOYSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- XQTDZHJQDNIRBY-UHFFFAOYSA-N 4-(hydroxymethyl)chromen-2-one Chemical compound C1=CC=CC2=C1OC(=O)C=C2CO XQTDZHJQDNIRBY-UHFFFAOYSA-N 0.000 description 1
- 241000606750 Actinobacillus Species 0.000 description 1
- 241000589996 Campylobacter rectus Species 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 241000588877 Eikenella Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000605986 Fusobacterium nucleatum Species 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical class NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001430197 Mollicutes Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000007990 PIPES buffer Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241001135221 Prevotella intermedia Species 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000723873 Tobacco mosaic virus Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000002920 hazardous waste Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 description 1
- 229910000271 hectorite Inorganic materials 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229910052901 montmorillonite Inorganic materials 0.000 description 1
- APVPOHHVBBYQAV-UHFFFAOYSA-N n-(4-aminophenyl)sulfonyloctadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 APVPOHHVBBYQAV-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
Definitions
- Organic solvents such as phenol and chloroform are traditionally used in techniques employed to isolate nucleic acid from procary ⁇ tic and eucaryotic cells or from complex biological samples. Nucleic acid isolations typically begin with an enzymatic digest performed with proteases followed by cell lysis using ionic detergents, and then extraction with phenol or a phenol/chloroform combination. The organic and aqueous phases are separated and nucleic acid which has partitioned into the aqueous phase is recovered by precipitation with alcohol.
- phenol or a phenol/chloroform mixture is corrosive to human skin and is considered as hazardous waste, which must be carefully handled and properly discarded. Further, the extraction method is time consuming and laborious. Marmur, J. Mol . Biol .
- chaotropic agents such as guanidinium thiocyanate (GnSCN) are widely used to lyse and release nucleic acid from cells into solution, largely due to the fact that chaotropic salts inhibit nucleases and proteases.
- GnSCN guanidinium thiocyanate
- nucleic acids all of the above traditional nucleic acid extraction procedures, thus, require the use of toxic compounds such as phenol and/or chloroform.
- researchers have long sought safer effective extraction procedures. for the extraction of nucleic acids.
- methods are described for isolating nucleic acid from a sample containing a mixture of nucleic acids and other biological compounds, wherein the sample is combined with an extraction solution containing at least one organic compound, such as benzyl alcohol or a benzyl alcohol derivative, forming an aqueous and non-aqueous phase.
- the nucleic acid is isolated from the aqueous phase.
- the resulting combined solution also contains bentonite or Macaloid, as defined below.
- the sample will first be combined with a lysing agent before extraction.
- the lysing agents preferred are chaotropic salts, such as guanidinium hydrochloride (GuHCl) and guanidinium isothiocyanate (GuSCN) .
- FIGURES Figure 1 shows the electrophoretic profile of total nucleic acids (chromosomal DNA and RNA) extracted using as the organic phase: 2-methyl-benzyl alcohol in lane 1; 4-methoxy- benzyl alcohol in lane 2; 3-ethoxy-benzyl alcohol in lane 3; 4-phenoxy-benzyl alcohol in lane 4; benzyl-alcohol in lane 5; and phenol in lane 6.
- Figure 2 shows the electrophoretic profile of total nucleic acids from extracted fecal samples using benzyl alcohol and bentonite.
- lane 1 is shown the electrophoretic profile of total nucleic acids isolated from fecal samples spiked with bacteria (Bacteroides gingivalis) when the extraction solution is composed of benzyl alcohol and 1% W/V bentonite.
- lane 2 shows the profile when the extraction solution is composed of phenol. In both extractions, the recovery of total nucleic acids is comparable, and 16S and 23S rRNAs are isolated in the intact form.
- the extraction methods of the present invention may be applied to a sample containing a biological mixture of nucleic acids (ribonucleic acid (RNA) and/or deoxyribonucleic acid (DNA) ) and other biological compounds, which are not nucleic acids.
- a sample may include any aqueous mixture of biological material which contains nucleic acids, including complex biological mixtures of any eucaryotic and/or procaryotic cells, including protoplasts, or other biological materials which may harbor nucleic acids.
- tissue culture animal cells animal tissue (e.g., heart, liver or brain, homogenized in lysis buffer) , feces, blood cells, reticulocytes, lymphocytes, plant cells or other cells sensitive to osmotic shock, and cells of bacteria, yeasts, viruses, mycoplasmas, protozoa, rickettsia, fungi and other small microbial cells and the like.
- the nucleic acid sample to be assayed or to serve as a source for the extraction of nucleic acids is combined with an extraction solution which allows for the separation of the nucleic acids in the sample from the other biological components resident in the sample.
- the extraction solutions comprise benzyl alcohol, derivatives of benzyl alcohol or other solvents with similar properties.
- the solvent must effectively cause the nucleic acids to be isolated from other biological components by partitioning the nucleic acids into an aqueous phase upon mixing the extraction solution with, an aqueous sample.
- the extraction solution will typically comprise an organic composition having an organic compound with the following properties:
- R 2 , R 3 and R* must be -H;
- R 2 is -C 6 H 5 , -0CH 2 C 6 H 5 , or -CH 2 C 6 H 5 ,
- R 3 must be -CH 3 , -OH, -Cl, -Br, -F, -I,
- R 1 is -(CH 2 ) n OH and n is 2 to 6, then R 3 and R* must both be -H.
- Formula I is intended to include all iso er forms of the alkyls, both branched and unbranched. Unless otherwise stated, all number ranges are inclusive of the stated range, with the use of zero referring to the absence of the element. For example, -(CH 2 ) n CH 3 , in which n is 0 to 2, refers to the three components: -CH 3 , -CH 2 CH 3 and -CH 2 CH 2 CH 3 .
- HC 6 H 5 is a benzene ring.
- R 3 and R* are both -H.
- the bentonite is first water-saturated and added to the extraction solution.
- Macaloid® a clay
- Bentone® are available from N.L. Chemicals, Hightstown, * N. . Bentone® is particularly suitable for use within the present invention because the particulate matter remains in relatively homogeneous suspension for extended periods of time, as compared to bentonite and Macaloid®. It may be necessary to first purify the nuclease inhibitor, for instance bentonite or Macaloid®, as described in Sambrook et al . , Molecular Cloning - A Laboratory Manual , Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (1989) , which is incorporated by reference herein. For efficient extraction, it is preferred that small uniform particles be used.
- the inclusion of dye in the extraction solution results in a colored organic phase and a colorless aqueous phase, thereby provided enhanced delineation of the two phases during the extraction process.
- the dye concentration is sufficient to provide visual contrast between the aqueous and organic phases, and typically is in the range of about 0.0005- 0.01% (w/v) . Because the dye is resident in the organic phase, the preferred organic compound may vary with choice of dye.
- the biological samples are typically lysed through the use of lysing agents, prior to or during extraction, to disturb the protein structure and to release the nucleic acid. Preferably, the sample will be subjected to lysis prior to the addition of the extraction solution. Any lysing agents typically used in nucleic acid extraction procedures are appropriate, such as SDS, lysozyme, Proteinase K in various combinations with chaotropic agents, or any other agent which would weaken or disrupt the integrity of the cell membrane.
- Chaotropic agents which disturb the secondary and tertiary structure of proteins (for example, guanidinium salts such as guanidinium hydr ⁇ chloride (GuHCl) , guanidinium isothio ⁇ yanate (GuSCN) , urea or other isothiocyanates) , may be used as lysing agents, in combination with or prior to the extraction solution, to dissociate nucleic acids and inhibit nucleases.
- guanidinium salts such as guanidinium hydr ⁇ chloride (GuHCl) , guanidinium isothio ⁇ yanate (GuSCN) , urea or other isothiocyanates
- chaotropic agents in the extraction and hybridization of nucleic acids is described in E.P Publication No. 0 127 327, which is incorporated by reference herein.
- labels include ligands which bind to labelled antibodies, fluorophores, che iluminescent agents, enzymes, and antibodies which can serve as specific binding pair members for a labelled ligand.
- the choice of label depends on sensitivity required, ease of conjugation with the probe, stability requirements, and available instrumentation.
- nucleic acid Precipitation of the nucleic acid was allowed to occur for 5 minutes at 19°C. The nucleic acids were then pelleted from
- Fecal samples in transport medium (Trend Fekal** Enteric Plus Transport System, Trend Scientific Inc., St. Paul, Minnesota) were aliquoted into 100 ⁇ l portions. Each aliquot was lysed with 300 ⁇ l of GuSCN lysis solution, as in Example 1, and were spiked with 5 x 10 8 Bacteriodes gingivalis cells. Following spiking, the samples were divided into two equal sets.
- the solid supports were then washed 5 times with APB, TMNZ (0.05 M Tris (pH 9.5), 1 mM MgCl 2 , 0.5 mM ZnCl 2 ) , and then the presence of alkaline phosphatase was determined by incubating the nylon beads with 150 ⁇ l of 0.5 mM 4-methyl-umbelliferyl phosphate (4-hydroxy- methyl coumarin) in black microtiter well strips (Dynatek Laboratories, Chantilly, VA) . Incubation was for 30 minutes at 37°C. The solution was then decanted and placed in a 96 well microtiter plate. The plates were then directly read using a Fluoroskan II fluorometer (Flow Laboratories, McLean, VA) using an excitation wavelength of 360 nm and an emission wavelength of 456 nm. The results are shown in Table 1 below.
- DNA extracted according to the protocol set forth in this Example is suitable for use in target amplification procedures, such as PCR (polymerase chain reaction) .
- target amplification procedures such as PCR (polymerase chain reaction) .
- PCR polymerase chain reaction
- Table 3 compares extraction of DNA from whole blood using a Proteinase K/phenol extraction method versus the extraction method of this Example. Briefly, three PCR-positive HTLV-I blood samples and five control blood samples (HTLV-I negative by PCR) were collected in tubes containing sodium EDTA. Each of the positive samples was serially diluted in 5- fold steps with the control blood. Duplicate 100 ⁇ l blood samples were extracted using a Proteinase K/phenol procedure (see, for example, Sambrook et al . , in "Molecular Cloning. A Laboratory Manual", Cold Spring Harbor Laboratory Press, New or , ; . guc , n mp ca ons.
- the preparation was centrifuged at 12,000 x g for 5 minutes. The supernatant was discarded, the pellet was air dried, and the nucleic acid pellet was then resuspended in RNase-free water or appropriate buffer to a desired concentration.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Saccharide Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69130394T DE69130394T2 (de) | 1990-07-13 | 1991-07-12 | Nicht-ätzende zusammensetzung und verfahren zur gewinnung von nukleinsäuren |
CA002087105A CA2087105C (fr) | 1990-07-13 | 1991-07-12 | Composition non corrosive et methodes utilisees pour extraire les acides nucleiques |
EP91914813A EP0539515B1 (fr) | 1990-07-13 | 1991-07-12 | Composition non corrosive et procedes utiles dans l'extraction d'acides nucleiques |
JP03513632A JP3102569B2 (ja) | 1990-07-13 | 1991-07-12 | 核酸の抽出に有用な非腐食性組成物および方法 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55274590A | 1990-07-13 | 1990-07-13 | |
US552,745 | 1990-07-13 | ||
US649,389 | 1991-02-01 | ||
US07/649,389 US5130423A (en) | 1990-07-13 | 1991-02-01 | Non-corrosive compositions and methods useful for the extraction of nucleic acids |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992000983A1 true WO1992000983A1 (fr) | 1992-01-23 |
Family
ID=27070123
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1991/004932 WO1992000983A1 (fr) | 1990-07-13 | 1991-07-12 | Composition non corrosive et procedes utiles dans l'extraction d'acides nucleiques |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0539515B1 (fr) |
JP (1) | JP3102569B2 (fr) |
AT (1) | ATE172466T1 (fr) |
CA (1) | CA2087105C (fr) |
DE (1) | DE69130394T2 (fr) |
ES (1) | ES2125869T3 (fr) |
WO (1) | WO1992000983A1 (fr) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0554034A1 (fr) * | 1992-01-28 | 1993-08-04 | Piotr Chomczynski | Produit planche-stable et procédé pour isoler RNA, DNA et proteines |
WO1994016103A3 (fr) * | 1993-01-08 | 1994-09-01 | Hybridon Inc | Detection d'oligonucleotides synthetiques extraits de liquides ou de tissus organiques |
WO1996000228A1 (fr) * | 1994-06-23 | 1996-01-04 | Dade International Inc. | Procede d'isolation rapide d'acide nucleique |
US5558992A (en) * | 1993-01-08 | 1996-09-24 | Hybridon, Inc. | Detection of synthetic oligonucleotides extracted from body fluids or tissues |
WO1997005248A3 (fr) * | 1995-07-31 | 1997-03-06 | Piotr Chomczynski | Solution contenant un agent chaotrope et son procede d'utilisation pour l'isolation d'adn, d'arn et de proteines |
EP0792932A4 (fr) * | 1995-08-21 | 1999-10-20 | Sanko Junyaku Kk | Co-precipitant et procede d'extraction d'acides nucleiques |
EP0853680A4 (fr) * | 1995-10-02 | 2000-09-13 | Novagen Inc | Procede permettant de precipiter un acide nucleique a l'aide d'un porteur visible |
WO2002014548A1 (fr) * | 2000-08-10 | 2002-02-21 | Applied Gene Technologies, Inc. | Compositions et procedes de traitement et d'amplification d'echantillons d'acides nucleiques |
US6448047B2 (en) | 1999-07-30 | 2002-09-10 | Applied Gene Technologies, Inc. | Sample processing to release nucleic acids for direct detection |
WO2003097831A1 (fr) * | 2002-05-17 | 2003-11-27 | Gl Bio Tech Gmbh | Procede d'extraction et de purification d'acides nucleiques |
WO2004108925A1 (fr) * | 2003-06-04 | 2004-12-16 | Qiagen As | Methode d'isolation sequentielle d'adn et d'arn a partir du meme echantillon contenant des acides nucleiques |
WO2005083122A3 (fr) * | 2004-02-27 | 2006-03-23 | Id Voor Groningen En Drenthe S | Methode de detection de micro-organisme dans un echantillon fecal |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2153215A1 (fr) * | 1994-07-06 | 1996-01-07 | Lu Wang | Traitement de tissus enchasses dans la paraffine pour l'analyse genique |
DE10222133A1 (de) * | 2002-05-17 | 2003-12-04 | Gl Biotech Gmbh | Verfahren zur Nukleinsäure-Extraktion und Nukleinsäure-Reinigung |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4440778A (en) * | 1981-02-26 | 1984-04-03 | Kowa Co., Ltd. | Anti-inflammatory analgesic cataplasm and process for producing the same |
-
1991
- 1991-07-12 ES ES91914813T patent/ES2125869T3/es not_active Expired - Lifetime
- 1991-07-12 DE DE69130394T patent/DE69130394T2/de not_active Expired - Lifetime
- 1991-07-12 EP EP91914813A patent/EP0539515B1/fr not_active Expired - Lifetime
- 1991-07-12 WO PCT/US1991/004932 patent/WO1992000983A1/fr active IP Right Grant
- 1991-07-12 CA CA002087105A patent/CA2087105C/fr not_active Expired - Lifetime
- 1991-07-12 AT AT91914813T patent/ATE172466T1/de not_active IP Right Cessation
- 1991-07-12 JP JP03513632A patent/JP3102569B2/ja not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4440778A (en) * | 1981-02-26 | 1984-04-03 | Kowa Co., Ltd. | Anti-inflammatory analgesic cataplasm and process for producing the same |
Non-Patent Citations (2)
Title |
---|
Biochemical Journal, Volume 64, issued 1956, KIRBY, "A New Method for the Isolation of Ribonucleic Acids from Mammalian Tissues", pages 405-408, see entire document. * |
Biochemical Journal, Volume 66, issued 1957, KIRBY, "A New Method for the Isolation of Deoxyribonucleic Acids: Evidence on the Nature of Bonds between Deoxyribonucleic Acid and Protein", pages 495-504, see entire document. * |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0554034A1 (fr) * | 1992-01-28 | 1993-08-04 | Piotr Chomczynski | Produit planche-stable et procédé pour isoler RNA, DNA et proteines |
WO1994016103A3 (fr) * | 1993-01-08 | 1994-09-01 | Hybridon Inc | Detection d'oligonucleotides synthetiques extraits de liquides ou de tissus organiques |
US5558992A (en) * | 1993-01-08 | 1996-09-24 | Hybridon, Inc. | Detection of synthetic oligonucleotides extracted from body fluids or tissues |
AU678821B2 (en) * | 1993-01-08 | 1997-06-12 | Hybridon, Inc. | Detection of synthetic oligonucleotides extracted from body fluids or tissues |
US5693466A (en) * | 1993-01-08 | 1997-12-02 | Hybridon, Inc. | Detection of synthetic oligonucleotides extracted from body fluids or tissues |
WO1996000228A1 (fr) * | 1994-06-23 | 1996-01-04 | Dade International Inc. | Procede d'isolation rapide d'acide nucleique |
WO1997005248A3 (fr) * | 1995-07-31 | 1997-03-06 | Piotr Chomczynski | Solution contenant un agent chaotrope et son procede d'utilisation pour l'isolation d'adn, d'arn et de proteines |
US5945515A (en) * | 1995-07-31 | 1999-08-31 | Chomczynski; Piotr | Product and process for isolating DNA, RNA and proteins |
EP0792932A4 (fr) * | 1995-08-21 | 1999-10-20 | Sanko Junyaku Kk | Co-precipitant et procede d'extraction d'acides nucleiques |
US6815541B1 (en) | 1995-08-21 | 2004-11-09 | Palma Bee'z Research Institute Co., Ltd. | Coprecipitant and method for extracting nucleic acids |
EP0853680A4 (fr) * | 1995-10-02 | 2000-09-13 | Novagen Inc | Procede permettant de precipiter un acide nucleique a l'aide d'un porteur visible |
US6448047B2 (en) | 1999-07-30 | 2002-09-10 | Applied Gene Technologies, Inc. | Sample processing to release nucleic acids for direct detection |
WO2002014548A1 (fr) * | 2000-08-10 | 2002-02-21 | Applied Gene Technologies, Inc. | Compositions et procedes de traitement et d'amplification d'echantillons d'acides nucleiques |
WO2003097831A1 (fr) * | 2002-05-17 | 2003-11-27 | Gl Bio Tech Gmbh | Procede d'extraction et de purification d'acides nucleiques |
WO2004108925A1 (fr) * | 2003-06-04 | 2004-12-16 | Qiagen As | Methode d'isolation sequentielle d'adn et d'arn a partir du meme echantillon contenant des acides nucleiques |
WO2005083122A3 (fr) * | 2004-02-27 | 2006-03-23 | Id Voor Groningen En Drenthe S | Methode de detection de micro-organisme dans un echantillon fecal |
Also Published As
Publication number | Publication date |
---|---|
CA2087105C (fr) | 2000-09-12 |
DE69130394T2 (de) | 1999-04-08 |
EP0539515B1 (fr) | 1998-10-21 |
EP0539515A4 (fr) | 1995-04-26 |
JPH05508658A (ja) | 1993-12-02 |
JP3102569B2 (ja) | 2000-10-23 |
ES2125869T3 (es) | 1999-03-16 |
ATE172466T1 (de) | 1998-11-15 |
DE69130394D1 (de) | 1998-11-26 |
EP0539515A1 (fr) | 1993-05-05 |
CA2087105A1 (fr) | 1992-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5393672A (en) | Non toxic compositions and methods useful for the extraction of nucleic acids | |
EP0539515B1 (fr) | Composition non corrosive et procedes utiles dans l'extraction d'acides nucleiques | |
RU2241004C2 (ru) | Композиция и способ для выделения нуклеиновых кислот из комплексных материалов с применением антихаотропной соли | |
Boom et al. | Rapid and simple method for purification of nucleic acids | |
US5124444A (en) | Lactam-containing compositions and methods useful for the extraction of nucleic acids | |
Cullen et al. | Simple and rapid method fordirect extraction of microbial DNA fromsoil for PCR | |
EP1527175B1 (fr) | Procedes et systemes de detection et d'isolation d'une sequence nucleotidique | |
Sayler et al. | Applications of molecular techniques to soil biochemistry | |
Holben | Isolation and purification of bacterial DNA from soil | |
EP2478087B1 (fr) | Compositions et méthodes pour la récupération d'acides nucléiques ou de protéines à partir d'échantillons de tissus fixés dans des milieux de cytologie | |
WO2000065041A1 (fr) | Procede de purification d'acides nucleiques a l'aide de carbure de silicium | |
JPH11501504A (ja) | 核酸の単離方法 | |
JP2004534515A (ja) | 核酸を抽出するための組成物および方法 | |
CN102776173A (zh) | 使用聚多卡醇和衍生物的核酸分离 | |
US20090130687A1 (en) | Formulations and method isolating nucleic acids from arbitrary complex starting materials and subsequent complex genetic materials | |
JP3491938B2 (ja) | Dnaの回収方法 | |
Siddappa et al. | Regeneration of commercial nucleic acid extraction columns without the risk of carryover contamination | |
US7074565B2 (en) | Preparation of DNA-containing extract for PCR amplification | |
WO1992018649A1 (fr) | Compositions et procedes d'extraction et d'hybridation ameliorees d'acide nucleique | |
CA2210012C (fr) | Composition non corrosive et methodes utiles pour l'extraction d'acides nucleiques | |
Selenska-Pobell | Direct and simultaneous extraction of DNA and RNA from soil | |
Brisco et al. | RNA purification: A rapid and versatile protocol for the isolation of total RNA | |
SAYLER et al. | JANET PACKARD University of Tennessee, Knoxville, Tennessee | |
Karunakaran et al. | Simple and rapid method for isolation of RNA from Gram-negative bacteria | |
Carter | General molecular biology |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1991914813 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2087105 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1991914813 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1991914813 Country of ref document: EP |